MCMedicalCodingSoftware
C8957

C8957: Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump

HCPCSActiveBETOS P6D

C8957 is a HCPCS Level II code for intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump. It belongs to the Outpatient Prospective Payment System section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Special coverage instructions apply

There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

Medically Unlikely Edits: units per day

The most units of C8957 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
2 units
MAI 3: Date of Service Edit: Clinical · CMS Policy
outpatient
2 units
MAI 3: Date of Service Edit: Clinical · CMS Policy

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.

The CMS record for C8957

Long descriptor
Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump

The official wording. This is what the code means.

Short descriptor
Prolonged iv inf, req pump

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2006

When CMS introduced the code.

BETOS
P6D

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
99: Other

Value not established.

Codes adjacent to C8957

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C8957 is not quite right, the correct code is very often within a few positions of it.

  • C8930Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision
  • C8931Magnetic resonance angiography with contrast, spinal canal and contents
  • C8932Magnetic resonance angiography without contrast, spinal canal and contents
  • C8933Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents
  • C8934Magnetic resonance angiography with contrast, upper extremity
  • C8935Magnetic resonance angiography without contrast, upper extremity
  • C8936Magnetic resonance angiography without contrast followed by with contrast, upper extremity
  • C8937Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)
  • C9014Injection, cerliponase alfa, 1 mgterminated
  • C9015Injection, c-1 esterase inhibitor (human), haegarda, 10 unitsterminated
  • C9016Injection, triptorelin extended release, 3.75 mgterminated
  • C9021Injection, obinutuzumab, 10 mgterminated
  • C9022Injection, elosulfase alfa, 1mgterminated
  • C9023Injection, testosterone undecanoate, 1 mgterminated
  • C9024Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabineterminated
  • C9025Injection, ramucirumab, 5 mgterminated
HCPCS Level II2026Q4-Oct· effective October 1, 2026